Q1 2022 Results

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 ≥2026 Cosentyx LCM canakinumab LCM Adakveo LCM aflibercept BioS Atectura LCM Kesimpta³ LCM Rydapt LCM secukinumab, AIN457 ACZ885 SEG101 SOK583 PSA IV Adjuvant NSCLC Sickle cell anaemia with crisis ped Neovascular age-related macular degeneration indacaterol + mometasone, QMF149 Asthma, pediatrics ofatumumab midostaurin, PKC412 Multiple sclerosis, pediatrics Acute myeloid leukemia, pediatrics Cosentyx LCM Cosentyx LCM Coartem LCM Beovu LCM Aimovig LCM Kymriah LCM Tabrecta LCM secukinumab, AIN457 secukinumab, AIN457 Hidradenitis suppurativa axSpA IV artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg brolucizumab, RTH258 erenumab, AMG334 tisagenlecleucel, CTL019 capmatinib, INC280 Diabetic retinopathy Pediatric Migraine 1L high risk ALL, pediatrics & young adults NSCLC Entresto EU1 LCM denosumab BioS Cosentyx LCM Cosentyx LCM Cosentyx LCM Leqvio LCM sacubitril/valsartan, LCZ696 GP2411 secukinumab, AIN457 secukinumab, AIN457 secukinumab, AIN457 KJX839 Pediatric CHF anti RANKL mAb GCA Lichen Planus Lupus Nephritis CVRR-LDLC Tafinlar + Mekinist LCM Kisqali LCM Jakavi LCM Leqvio LCM Jakavi LCM Mayzent4 LCM dabrafenib + trametinib, DRB436 ribociclib, LEE011 ruxolitinib, INC424 KJX839 ruxolitinib, INC424 siponimod, BAF312 HGG/LGG - Pediatrics. HR+/HER2- BC (adj) Pediatrics Acute GVHD Ped Hyperlipidemia Myelofibrosis (combination) Multiple sclerosis, pediatrics Xolair LCM Lutathera LCM Jakavi LCM Piqray LCM omalizumab, IGE025 177Lu-oxodotreotide² ruxolitinib, INC424 alpelisib, BYL719 Auto-injector GEP-NET 1L G3 Pediatrics Chronic GVHD HER2+ adv BC Piqray LCM Tafinlar + Mekinist LCM Promacta LCM alpelisib, BYL719 TNBC dabrafenib + trametinib, DRB436 Thyroid cancer eltrombopag, ETB115 Radiation sickness syndrome Piqray LCM Zolgensma LCM alpelisib, BYL719 AVXS-101 OAV101 Ovarian cancer SMA IT Xolair LCM omalizumab, IGE025 Food allergy 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). 43 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation